This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
May is Skin Cancer Awareness Month! View this slideshow to learn the latest statistics in the United States, leading causes and preventive measures, and quick facts on melanoma, one of the most common types of skin cancer. Conquer cancer with knowledge.
Last modified: December 28, 2017
Subscribe to CONQUER: the patient voice® magazine
Receive timely cancer news & updates, patient stories, and more.